Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial / Petrylak, Dp; de Wit, R; Chi, Kn; Drakaki, A; Sternberg, Cn; Nishiyama, H; Castellano, D; Hussain, Sa; Flechon, A; Bamias, A; Yu, Ey; van der Heijden, Ms; Matsubara, N; Alekseev, B; Necchi, A; Geczi, L; Ou, Yc; Coskun, Hs; Su, Wp; Bedke, J; Gakis, G; Percent, Ij; Lee, Jl; Tucci, M; Semenov, A; Laestadius, F; Peer, A; Tortora, G; Safina, S; del Muro, Xg; Rodriguez-Vida, A; Cicin, I; Harputluoglu, H; Tagawa, St; Vaishampayan, U; Aragon-Ching, Jb; Hamid, O; Liepa, Am; Wijayawardana, S; Russo, F; Walgren, Ra; Zimmermann, Ah; Hozak, Rr; Bell-McGuinn, Km; Powles, T. - In: THE LANCET ONCOLOGY. - ISSN 1470-2045. - 21:1(2020), pp. 105-120. [10.1016/S1470-2045(19)30668-0]